373 related articles for article (PubMed ID: 20634777)
41. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
[TBL] [Abstract][Full Text] [Related]
42. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
43. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
44. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
45. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.
Zhang ZH; Liu HY; Hernandez-Da Mota SE; Romano MR; Falavarjani KG; Ahmadieh H; Xu X; Liu K
Am J Ophthalmol; 2013 Jul; 156(1):106-115.e2. PubMed ID: 23791371
[TBL] [Abstract][Full Text] [Related]
46. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.
Gupta A; Bansal R; Gupta V; Dogra MR
Int Ophthalmol; 2012 Apr; 32(2):135-44. PubMed ID: 22450558
[TBL] [Abstract][Full Text] [Related]
47. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
48. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
49. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy.
Lee SJ; Koh HJ
J Ocul Pharmacol Ther; 2009 Apr; 25(2):173-4. PubMed ID: 19284326
[TBL] [Abstract][Full Text] [Related]
50. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.
Yeoh J; Williams C; Allen P; Buttery R; Chiu D; Clark B; Essex R; McCombe M; Qureshi S; Campbell WG
Clin Exp Ophthalmol; 2008 Jul; 36(5):449-54. PubMed ID: 18942219
[TBL] [Abstract][Full Text] [Related]
51. [Analysis of the Cochrane Review: Anti-vascular Endothelial Growth Factor for Prevention of Postoperative Vitreous Cavity Hemorrhage after Vitrectomy for Proliferative Diabetic Retinopathy. Cochrane Database Syst Rev. 2015;8:CD008214.].
Sousa DC; Leal I; Costa J; Vaz-Carneiro A
Acta Med Port; 2017 Aug; 30(7-8):513-516. PubMed ID: 28926323
[TBL] [Abstract][Full Text] [Related]
52. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
53. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.
Minnella AM; Savastano CM; Ziccardi L; Scupola A; Falsini B; Balestrazzi E
Acta Ophthalmol; 2008 Sep; 86(6):683-7. PubMed ID: 17995986
[TBL] [Abstract][Full Text] [Related]
54. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
55. [Efficiency of air tamponade in prevention of early recurrence of vitreal hemorrhage in diabetic patients with vitrectomy].
Brănişteanu D; Danielescu C; Irimia A; Robu M
Oftalmologia; 2006; 50(2):62-7. PubMed ID: 16927761
[TBL] [Abstract][Full Text] [Related]
56. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.
Jiang T; Gu J; Zhang P; Chen W; Chang Q
BMC Ophthalmol; 2020 Feb; 20(1):43. PubMed ID: 32013913
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.
Arevalo JF; Wu L; Sanchez JG; Maia M; Saravia MJ; Fernandez CF; Evans T
Eye (Lond); 2009 Jan; 23(1):117-23. PubMed ID: 17891058
[TBL] [Abstract][Full Text] [Related]
58. Optic atrophy after anti-vascular endothelial growth factor injection in diabetic patients with proliferative diabetic retinopathy.
Singalavanija A; Hemarat K; Kedkovid N; Tanterdtham J; Namatra C; Trinavarat A; Rodanant N; Thoongsuwan S
J Med Assoc Thai; 2013 Mar; 96(3):318-23. PubMed ID: 23539935
[TBL] [Abstract][Full Text] [Related]
59. Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial.
Aleman I; Castillo Velazquez J; Rush SW; Rush RB
Br J Ophthalmol; 2019 Dec; 103(12):1740-1746. PubMed ID: 30705040
[TBL] [Abstract][Full Text] [Related]
60. Anterior retinal cryotherapy and intravitreal injection of bevacizumab in the treatment of nonclearing vitreous hemorrhage in proliferative diabetic retinopathy.
Hsieh MC; Yeh PT; Yang CM; Yang CH
J Ocul Pharmacol Ther; 2014 May; 30(4):353-8. PubMed ID: 24359129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
